Capecitabine
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Capecitabine Product Information
Capecitabine is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Capecitabine. The product is supplied by Clearsynth under CAT No. CS-O-01072.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Capecitabine
CAS No.
154361-50-9
CAT No.
CS-O-01072
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C15H22FN3O6
Molecular Weight
359.36
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Capecitabine is supplied with detailed characterization data compliant with regulatory guideline. Capecitabine can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Capecitabine.
Overview
For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who havq
Synonyms
Capecitabine
Application Notes
For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who havq
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.